5-cyclopentyl-6-(2,2,2-trifluoro-ethoxy)-nicotinic acid | 1426998-73-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-cyclopentyl-6-(2,2,2-trifluoro-ethoxy)-nicotinic acid
• 英文别名: 5-cyclopentyl-6-(2,2,2-trifluoroethoxy)-3-pyridinecarboxylic acid；5-cyclopentyl-6-(2,2,2-trifluoroethoxy)pyridine-3-carboxylic acid
• CAS: 1426998-73-3
• 化学式: C₁₃H₁₄F₃NO₃
• 分子量: 289.254
• InChiKey: KWOYMTABCJRVMM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  C-(3-trifluoromethyl-1,2,4-oxadiazol-5-yl)-methylamine 、 5-cyclopentyl-6-(2,2,2-trifluoro-ethoxy)-nicotinic acid 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.5h， 以38.7%的产率得到5-cyclopentyl-6-(2,2,2-trifluoro-ethoxy)-N-(3-trifluoromethyl-[1,2,4]oxadiazol-5-ylmethyl)-nicotinamide
  参考文献：
  名称：

  5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES

  摘要：

  本发明涉及式中R1至R4在说明书中定义的化合物，以及其药学上可接受的盐、制造方法、含有它们的药物组成物以及它们作为治疗和/或预防可用高密度脂蛋白胆固醇升高剂治疗的疾病的药物的用途，例如特别是失调脂质代谢、动脉硬化和心血管疾病。

  公开号：

  US20130065907A1

文献信息

• 3-PYRIDINE CARBOXYLIC ACID HYDRAZIDES
  申请人：Grether Uwe

  公开号：US20130065876A1

  公开（公告）日：2013-03-14

  The present invention relates to compounds of formula I, wherein R 1 to R 5 are defined in the description and claims, and to pharmaceutically acceptable salts thereof. The present invention relates also to the manufacture of said compounds, pharmaceutical compositions containing them and methods for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as dyslipidemia, atherosclerosis and cardiovascular diseases.

  本发明涉及公式I的化合物，其中R1至R5在描述和权利要求中定义，并且其药学上可接受的盐。本发明还涉及所述化合物的制备，含有它们的药物组合物以及用于治疗和/或预防可以用HDL-胆固醇升高剂治疗的疾病的方法，例如脂质代谢异常、动脉粥样硬化和心血管疾病。
• [EN] 3 -PYRIDINE CARBOXYLIC ACID HYDRAZIDES AS HDL-CHOLESTEROL RAISING AGENTS<br/>[FR] HYDRAZIDES D'ACIDE 3-PYRIDINE-CARBOXYLIQUE EN TANT QU'AGENTS D'ÉLÉVATION DU CHOLESTÉROL HDL
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013037703A1

  公开（公告）日：2013-03-21

  The present invention relates to compounds of the formula wherein R1 to R5 are defined in the description and claims, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis and cardiovascular diseases.

  本发明涉及以下式中R1至R5在描述和权利要求中定义的化合物，以及其药学上可接受的盐，它们的制备，含有它们的药物组合物以及它们作为治疗和/或预防可用高密度脂蛋白胆固醇升高剂治疗的疾病的药物的用途，例如特别是脂质代谢异常，动脉粥样硬化和心血管疾病。
• [EN] 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES<br/>[FR] 5-CYCLOALKYL- OU 5-HÉTÉROCYCLYL-NICOTINAMIDES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013037721A1

  公开（公告）日：2013-03-21

  The present invention relates to compounds of the formula I wherein R1 to R4 are defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis and cardiovascular diseases.

  本发明涉及到公式I中定义的化合物，其中R1至R4在说明书中有定义，以及其药学上可接受的盐、其制备方法、含有它们的制药组合物以及它们作为药物用于治疗和/或预防可以使用高密度脂蛋白胆固醇升高剂治疗的疾病，例如特别是血脂异常、动脉粥样硬化和心血管疾病。
• 5-cycloalkyl- or 5-heterocyclyl-nicotinamides
  申请人：Grether Uwe

  公开号：US08629166B2

  公开（公告）日：2014-01-14

  The present invention relates to compounds of the formula wherein R1 to R4 are defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis and cardiovascular diseases.

  本发明涉及公式中R1至R4在说明中定义的化合物，以及其药学上可接受的盐，其制造、含有它们的制药组合物以及它们作为药物治疗和/或预防可以用高密度脂蛋白胆固醇升高剂治疗的疾病，如特别是血脂异常、动脉硬化和心血管疾病的用途。
• 3-pyridine carboxylic acid hydrazides
  申请人：Grether Uwe

  公开号：US08648099B2

  公开（公告）日：2014-02-11

  The present invention relates to compounds of formula I, wherein R1 to R5 are defined in the description and claims, and to pharmaceutically acceptable salts thereof. The present invention relates also to the manufacture of said compounds, pharmaceutical compositions containing them and methods for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as dyslipidemia, atherosclerosis and cardiovascular diseases.

  本发明涉及式I的化合物，其中R1至R5在说明书和权利要求中定义，并且其药学上可接受的盐。本发明还涉及制造上述化合物、含有它们的药物组合物以及用于治疗和/或预防可以用高密度脂蛋白胆固醇升高剂治疗的疾病的方法，例如血脂异常、动脉粥样硬化和心血管疾病。